Abstract
Alcohol use disorder is a complex syndrome with multiple treatment points including drug-induced pathology, withdrawal management, behavioral/cognitive strategies, and relapse prevention. These different components may be complicated by genotype and phenotype. A huge milestone for the treatment of alcohol use disorder across several countries in the last 10 years was the introduction of practice guidelines integrating clinical expertise and research evidence. These provide a summary of interventions that have been shown to be effective following rigorous and replicated clinical trials. Inspection of these guidelines reveals good consistency, but little evidence of progress in treatment approaches for alcohol use disorder over the past decade. In this mini-review, we discuss emerging treatments for alcohol use disorder that may supplement or improve the evidence-based treatments that are currently recommended. New medications, the emergence of digital technology, and other novel approaches such as transcranial magnetic stimulation are all discussed with reference to treatments already in practice. We also consider how individual differences in genotype and phenotype may affect outcomes. Together with improvements in technology, this knowledge offers a powerful tool for designing personalized approaches to treatment, and hence improving prognosis for rehabilitation programs.
Similar content being viewed by others
References
Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G (2000) Ability of baclofen in reducing alcohol craving and intake: II—preliminary clinical evidence. Alcohol Clin Exp Res 24(1):67–71
Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G (2002a) Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 37(5):504–508
Addolorato G, Caputo F, Capristo E, Janiri L, Bernardi M, Agabio R, Colombo G, Gessa GL, Gasbarrini G (2002b) Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med 112(3):226–229
Addolorato G, Antonelli M, Cocciolillo F, Vassallo GA, Tarli C, Sestito L, Mirijello A, Ferrulli A, Pizzuto DA, Camardese G, Miceli A, Diana M, Giordaon A, Gasbarrini A, Di Giuda D (2017) Deep transcranial magnetic stimulation of the dorsolateral prefrontal cortex in alcohol use disorder patients: effects on dopamine transporter availability and alcohol intake. Eur Neuropsychopharmacol 27(5):450–461. https://doi.org/10.1016/j.euroneuro.2017.03.008
Agabio R, Colombo G (2014) GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. Front Neurosci 8:140. https://doi.org/10.3389/fnins.2014.00140
Alba-Ferrara L, Fernandez F, Salas R, de Erausquin GA (2014) Transcranial magnetic stimulation and deep brain stimulation in the treatment of alcohol dependence. Addict Disord Their Treat 13(4):159–169. https://doi.org/10.1097/ADT.0b013e31829cf047
Ameisen O (2005) Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol 40(2):147–150. https://doi.org/10.1093/alcalc/agh130
American Psychiatric Association (2006) Practice guideline for the treatment of patients with substance use disorders. American Psychiatric Association
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Arlington
Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Combine Study Research Group (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295(17):2003–2017. https://doi.org/10.1001/jama.295.17.2003
Apollonio D, Philipps R, Bero L (2016) Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database Syst Rev 11:CD010274. https://doi.org/10.1002/14651858.CD010274.pub2
Arias AJ, Feinn R, Oncken C, Covault J, Kranzler HR (2010) Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J Clin Psychopharmacol 30(3):318–322. https://doi.org/10.1097/JCP.0b013e3181db38bb
Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3(8):673–683. https://doi.org/10.1038/nrd1468
Australian Government Department of Health and Ageing (2009) Guidelines for the treatment of alcohol problems. Commonwealth of Australia, Sydney
Balhara Y, Verma R (2014) A review of web based interventions focusing on alcohol use. Ann Med Health Sci Res 4(4):472–480. https://doi.org/10.4103/2141-9248.139272
Bates ME, Bowden SC, Barry D (2002) Neurocognitive impairment associated with alcohol use disorders: implications for treatment. Exp Clin Psychopharmacol 10(3):193–212. https://doi.org/10.1037/1064-1297.10.3.193
Bates ME, Pawlak AP, Tonigan JS, Buckman JF (2006) Cognitive impairment influences drinking outcome by altering therapeutic mechanisms of change. Psychol Addict Behav 20(3):241–253. https://doi.org/10.1037/0893-164X.20.3.241
Bates ME, Buckman JF, Nguyen TT (2013) A role for cognitive rehabilitation in increasing the effectiveness of treatment for alcohol use disorders. Neuropsychol Rev 23(1):27–47. https://doi.org/10.1007/s11065-013-9228-3
Batki SL, Pennington DL (2014) Toward personalized medicine in the pharmacotherapy of alcohol use disorder: targeting patient genes and patient goals. Am J Psychiatry 171(4):391–394. https://doi.org/10.1176/appi.ajp.2014.14010061
Biton V (2007) Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 30(4):230–240. https://doi.org/10.1097/wnf.0b013e3180413d7d
Blaine SK, Sinha R (2017) Alcohol, stress, and glucocorticoids: from risk to dependence and relapse in alcohol use disorders. Neuropharmacology 122:136–147. https://doi.org/10.1016/j.neuropharm.2017.01.037
Blaine SK, Milivojevic V, Fox H, Sinha R (2016) Alcohol effects on stress pathways: impact on craving and relapse risk. Can J Psychiatr 61(3):145–153. https://doi.org/10.1177/0706743716632512
Blankers M, Koeter MW, Schippers GM (2011) Internet therapy versus internet self-help versus no treatment for problematic alcohol use: a randomized controlled trial. J Consult Clin Psychol 79(3):330–341. https://doi.org/10.1037/a0023498
Boggio PS, Sultani N, Fecteau S, Merabet L, Mecca T, Pascual-Leone A, Basaglia A, Fregni F (2008) Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: a double-blind, sham-controlled study. Drug Alcohol Depend 92(1–3):55–60. https://doi.org/10.1016/j.drugalcdep.2007.06.011
Breese GR, Sinha R, Heilig M (2011) Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse. Pharmacol Ther 129(2):149–171. https://doi.org/10.1016/j.pharmthera.2010.09.007
Bucknam W (2007) Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol 42(2):158–160. https://doi.org/10.1093/alcalc/agl091
Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T (2016) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 5:CD006103. https://doi.org/10.1002/14651858.CD006103.pub7
Caldwell LC, Schweinsburg AD, Nagel BJ, Barlett VC, Brown SA, Tapert SF (2005) Gender and adolescent alcohol use disorders on BOLD (blood oxygen level dependent) response to spatial working memory. Alcohol Alcohol 40(3):194–200. https://doi.org/10.1093/alcalc/agh134
Campbell AN, Nunes EV, Matthews AG, Stitzer M, Miele GM, Polsky D, Turrigiano E, Walters S, McClure EA, Kyle TL, Wahle A, Van Veldhuisen P, Goldman B, Babcock D, Stabile PQ, Winhusen T, Ghitza UE (2014) Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry 171(6):683–690. https://doi.org/10.1176/appi.ajp.2014.13081055
Caputo F, Vignoli T, Tarli C, Domenicali M, Zoli G, Bernardi M, Addolorato G (2016) A brief up-date of the use of sodium oxybate for the treatment of alcohol use disorder. Int J Environ Res Public Health 13(3):290. https://doi.org/10.3390/ijerph13030290
Carey KB, Scott-Sheldon LA, Carey MP, DeMartini KS (2007) Individual-level interventions to reduce college student drinking: a meta-analytic review. Addict Behav 32(11):2469–2494. https://doi.org/10.1016/j.addbeh.2007.05.004
Carey KB, Scott-Sheldon LA, Garey L, Elliott JC, Carey MP (2016) Alcohol interventions for mandated college students: a meta-analytic review. J Consult Clin Psychol 84(7):619–632. https://doi.org/10.1037/a0040275
Carroll KM, Kiluk BD (2017) Cognitive behavioral interventions for alcohol and drug use disorders: through the stage model and back again. Psychol Addict Behav. https://doi.org/10.1037/adb0000311
Carroll KM, Onken LS (2005) Behavioral therapies for drug abuse. Am J Psychiatry 162(8):1452–1460. https://doi.org/10.1176/appi.ajp.162.8.1452
Ceccanti M, Inghilleri M, Attilia ML, Raccah R, Fiore M, Zangen A, Ceccanti M (2015) Deep TMS on alcoholics: effects on cortisolemia and dopamine pathway modulation. A pilot study. Can J Physiol Pharmacol 93(4):283–290. https://doi.org/10.1139/cjpp-2014-0188
Cohn AM, Hunter-Reel D, Hagman BT, Mitchell J (2011) Promoting behavior change from alcohol use through mobile technology: the future of ecological momentary assessment. Alcohol Clin Exp Res 35(12):2209–2215. https://doi.org/10.1111/j.1530-0277.2011.01571.x
Collins FS, Varmus H (2015) A new initiative on precision medicine. N Engl J Med 372(9):793–795. https://doi.org/10.1056/NEJMp1500523
Conklin CA, Tiffany ST (2002) Applying extinction research and theory to cue-exposure addiction treatments. Addiction 97(2):155–167
Conway KP, Swendsen J, Husky MM, He JP, Merikangas KR (2016) Association of Lifetime Mental Disorders and Subsequent Alcohol and Illicit Drug Use: results from the National Comorbidity Survey-Adolescent Supplement. J Am Acad Child Adolesc Psychiatry 55(4):280–288. https://doi.org/10.1016/j.jaac.2016.01.006
Cristea IA, Kok RN, Cuijpers P (2016) The effectiveness of cognitive bias modification interventions for substance addictions: a meta-analysis. PLoS One 11(9):e0162226. https://doi.org/10.1371/journal.pone.0162226
da Silva MC, Conti CL, Klauss J, Alves LG, do Nascimento Cavalcante HM, Fregni F, Nakamura-Palacios EM (2013) Behavioral effects of transcranial direct current stimulation (tDCS) induced dorsolateral prefrontal cortex plasticity in alcohol dependence. J Physiol Paris 107(6):493–502. https://doi.org/10.1016/j.jphysparis.2013.07.003
den Uyl TE, Gladwin TE, Wiers RW (2015) Transcranial direct current stimulation, implicit alcohol associations and craving. Biol Psychol 105:37–42. https://doi.org/10.1016/j.biopsycho.2014.12.004
Dario A, Tomei G (2004) A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf 27(11):799–818
Dougherty DM, Lake SL, Hill-Kapturczak N, Liang Y, Karns TE, Mullen J, Roache JD (2015) Using contingency management procedures to reduce at-risk drinking in heavy drinkers. Alcohol Clin Exp Res 39(4):743–751. https://doi.org/10.1111/acer.12687
Dulin PL, Gonzalez VM (2017) Smartphone-based, momentary intervention for alcohol cravings amongst individuals with an alcohol use disorder. Psychol Addict Behav 31(5):601–607. https://doi.org/10.1037/adb0000292
Farris SP, Arasappan D, Hunicke-Smith S, Harris RA, Mayfield RD (2015) Transcriptome organization for chronic alcohol abuse in human brain. Mol Psychiatry 20(11):1438–1447. https://doi.org/10.1038/mp.2014.159
Feeney GF, Young RM, Connor JP, Tucker J, McPherson A (2002) Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term treatment outcomes for alcohol dependence improved? Aust N Z J Psychiatry 36(5):622–628
Fernandez AC, Yurasek AM, Merrill JE, Miller MB, Zamboanga BL, Carey KB, Borsari B (2017) Do brief motivational interventions reduce drinking game frequency in mandated students? An analysis of data from two randomized controlled trials. Psychol Addict Behav 31(1):36–45. https://doi.org/10.1037/adb0000239
Ferrer-Garcia M, Gutierrez-Maldonado J, Pla J (2013) Cue-elicited anxiety and craving for food using virtual reality scenarios. Stud Health Technol Inform 191:105–109
Fitzsimons H, Tuten M, Borsuk C, Lookatch S, Hanks L (2015) Clinician-delivered contingency management increases engagement and attendance in drug and alcohol treatment. Drug Alcohol Depend 152:62–67. https://doi.org/10.1016/j.drugalcdep.2015.04.021
Florez G, Saiz PA, Garcia-Portilla P, Alvarez S, Nogueiras L, Bobes J (2011) Topiramate for the treatment of alcohol dependence: comparison with naltrexone. Eur Addict Res 17(1):29–36. https://doi.org/10.1159/000320471
Fowler LA, Holt SL, Joshi D (2016) Mobile technology-based interventions for adult users of alcohol: a systematic review of the literature. Addict Behav 62:25–34. https://doi.org/10.1016/j.addbeh.2016.06.008
Foxcroft DR, Coombes L, Wood S, Allen D, Almeida Santimano NM, Moreira MT (2016) Motivational interviewing for the prevention of alcohol misuse in young adults. Cochrane Database Syst Rev 7:CD007025. https://doi.org/10.1002/14651858.CD007025.pub4
Frias J, Rodriguez R, Torres JM, Ruiz E, Ortega E (2000) Effects of acute alcohol intoxication on pituitary-gonadal axis hormones, pituitary-adrenal axis hormones, beta-endorphin and prolactin in human adolescents of both sexes. Life Sci 67(9):1081–1086
Furieri FA, Nakamura-Palacios EM (2007) Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 68(11):1691–1700
Gastpar M, Bonnet U, Boning J, Mann K, Schmidt LG, Soyka M et al (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 22(6):592–598
Gimeno C, Dorado ML, Roncero C, Szerman N, Vega P, Balanza-Martinez V, Alvarez FJ (2017) Treatment of comorbid alcohol dependence and anxiety disorder: review of the scientific evidence and recommendations for treatment. Front Psychiatry 8:173. https://doi.org/10.3389/fpsyt.2017.00173
Gladwin TE, Wiers CE, Wiers RW (2016) Cognitive neuroscience of cognitive retraining for addiction medicine: From mediating mechanisms to questions of efficacy. Prog Brain Res 224:323–344. https://doi.org/10.1016/bs.pbr.2015.07.021
Glasner-Edwards S, Rawson R (2010) Evidence-based practices in addiction treatment: review and recommendations for public policy. Health Policy 97(2–3):93–104. https://doi.org/10.1016/j.healthpol.2010.05.013
Gonzalez VM, Dulin PL (2015) Comparison of a smartphone app for alcohol use disorders with an internet-based intervention plus bibliotherapy: a pilot study. J Consult Clin Psychol 83(2):335–345. https://doi.org/10.1037/a0038620
Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B, Hasin DS (2015) Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 72(8):757–766. https://doi.org/10.1001/jamapsychiatry.2015.0584
Gustafson DH, McTavish FM, Chih MY, Atwood AK, Johnson RA, Boyle MG, Levy MS, Driscoll H, Chisholm SM, Dillenburg L, Isham A, Shah D (2014) A smartphone application to support recovery from alcoholism: a randomized clinical trial. JAMA Psychiatry 71(5):566–572. https://doi.org/10.1001/jamapsychiatry.2013.4642
Hammarberg A, Jayaram-Lindstrom N, Beck O, Franck J, Reid MS (2009) The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology 205(1):53–62. https://doi.org/10.1007/s00213-009-1515-6
Hoeppner BB, Schick MR, Kelly LM, Hoeppner SS, Bergman B, Kelly JF (2017) There is an app for that—or is there? A content analysis of publicly available smartphone apps for managing alcohol use. J Subst Abus Treat 82:67–73. https://doi.org/10.1016/j.jsat.2017.09.006
Houben K, Wiers RW, Jansen A (2011) Getting a grip on drinking behavior: training working memory to reduce alcohol abuse. Psychol Sci 22(7):968–975. https://doi.org/10.1177/0956797611412392
Ipser JC, Wilson D, Akindipe TO, Sager C, Stein DJ (2015) Pharmacotherapy for anxiety and comorbid alcohol use disorders. Cochrane Database Syst Rev 1:CD007505. https://doi.org/10.1002/14651858.CD007505.pub2
Jain KK (2010) Innovative diagnostic technologies and their significance for personalized medicine. Mol Diagn Ther 14(3):141–147. https://doi.org/10.2165/11536240-000000000-00000
Jain KK (2017) Personalized management of cardiovascular disorders. Med Princ Pract 26(5):399–414. https://doi.org/10.1159/000481403
Jiang S, Wu L, Gao X (2017) Beyond face-to-face individual counseling: a systematic review on alternative modes of motivational interviewing in substance abuse treatment and prevention. Addict Behav 73:216–235. https://doi.org/10.1016/j.addbeh.2017.05.023
Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361(9370):1677–1685. https://doi.org/10.1016/s0140-6736(03)13370-3
Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ (2004) Oral topiramate reduces the consequences of drinking and improves thequality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 61(9):905–912. https://doi.org/10.1001/archpsyc.61.9.905
Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298(14):1641–1651. https://doi.org/10.1001/jama.298.14.1641
Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ, Liu L, Penberthy JK, DiClemente CC, Li MD (2011) Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 168(3):265–275. https://doi.org/10.1176/appi.ajp.2010.10050755
Karpyak VM, Biernacka JM, Geske JR, Jenkins GD, Cunningham JM, Ruegg J et al (2014) Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. Transl Psychiatry 4:e462. https://doi.org/10.1038/tp.2014.103
Kaskutas LA (2009) Alcoholics anonymous effectiveness: faith meets science. J Addict Dis 28(2):145–157. https://doi.org/10.1080/10550880902772464
Kaskutas LA, Bond J, Avalos LA (2009) 7-year trajectories of Alcoholics Anonymous attendance and associations with treatment. Addict Behav 34(12):1029–1035. https://doi.org/10.1016/j.addbeh.2009.06.015
Kay-Lambkin FJ, Baker AL, Lewin TJ, Carr VJ (2009) Computer-based psychological treatment for comorbid depression and problematic alcohol and/or cannabis use: a randomized controlled trial of clinical efficacy. Addiction 104(3):378–388. https://doi.org/10.1111/j.1360-0443.2008.02444.x
Kelly JF, Yeterian JD, Cristello JV, Kaminer Y, Kahler CW, Timko C (2016) Developing and testing twelve-step facilitation for adolescents with substance use disorder: manual development and preliminary outcomes. Subst Abus 10:55–64. https://doi.org/10.4137/SART.S39635
Khadjesari Z, Murray E, Hewitt C, Hartley S, Godfrey C (2011) Can stand-alone computer-based interventions reduce alcohol consumption? A systematic review. Addiction 106(2):267–282. https://doi.org/10.1111/j.1360-0443.2010.03214.x
Khan A, Levy P, DeHorn S, Miller W, Compton S (2008) Predictors of mortality in patients with delirium tremens. Acad Emerg Med 15(8):788–790. https://doi.org/10.1111/j.1553-2712.2008.00187.x
Knapp CM, Sarid-Segal O, Richardson MA, Colaneri LS, Afshar M, Devine E et al (2010) Open label trial of the tolerability and efficacy of zonisamide in the treatment of alcohol dependence. Am J Drug Alcohol Abuse 36(2):102–105. https://doi.org/10.3109/00952991003674812
Knapp CM, Ciraulo DA, Sarid-Segal O, Richardson MA, Devine E, Streeter CC et al (2015) Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol 35(1):34–42. https://doi.org/10.1097/jcp.0000000000000246
Krampe H, Ehrenreich H (2010) Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Des 16(19):2076–2090
Kranzler HR, Pierucci-Lagha A, Feinn R, Hernandez-Avila C (2003) Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res 27(7):1150–1155. https://doi.org/10.1097/01.ALC.0000075547.77464.76
Kranzler HR, Smith RV, Schnoll R, Moustafa A, Greenstreet-Akman E (2017) Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?. Addiction 112(12):2086–2094
Krenek M, Maisto SA, Funderburk JS, Drayer R (2011) Severity of alcohol problems and readiness to change alcohol use in primary care. Addict Behav 36(5):512–515. https://doi.org/10.1016/j.addbeh.2010.12.023
Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, Veterans Affairs Naltrexone Cooperative Study, G (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345(24):1734–1739. https://doi.org/10.1056/NEJMoa011127
Kuhn J, Grundler TO, Bauer R, Huff W, Fischer AG, Lenartz D et al (2011) Successful deep brain stimulation of the nucleus accumbens in severe alcohol dependence is associated with changed performance monitoring. Addict Biol 16(4):620–623. https://doi.org/10.1111/j.1369-1600.2011.00337.x
Kushner MG, Sletten S, Donahue C, Thuras P, Maurer E, Schneider A et al (2009) Cognitive-behavioral therapy for panic disorder in patients being treated for alcohol dependence: moderating effects of alcohol outcome expectancies. Addict Behav 34(6–7):554–560. https://doi.org/10.1016/j.addbeh.2009.03.011
Kutscher S, Heise DJ, Banger M, Saller B, Michel MC, Gastpar M et al (2002) Concomitant endocrine and immune alterations during alcohol intoxication and acute withdrawal in alcohol-dependent subjects. Neuropsychobiology 45(3):144–149. https://doi.org/10.1159/000054955
Le Berre AP, Vabret F, Cauvin C, Pinon K, Allain P, Pitel AL, Eustache F, Beaunieux H (2012) Cognitive barriers to readiness to change in alcohol-dependent patients. Alcohol Clin Exp Res 36(9):1542–1549. https://doi.org/10.1111/j.1530-0277.2012.01760.
Lee JH, Kwon H, Choi J, Yang BH (2007) Cue-exposure therapy to decrease alcohol craving in virtual environment. Cyberpsychol Behav 10(5):617–623. https://doi.org/10.1089/cpb.2007.9978
Leggio L, Zywiak WH, Fricchione SR, Edwards SM, de la Monte SM, Swift RM, Kenna GA (2014) Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigation. Biol Psychiatry 76(9):734–741. https://doi.org/10.1016/j.biopsych.2014.03.019
Lemke S, Schutte KK, Brennan PL, Moos RH (2008) Gender differences in social influences and stressors linked to increased drinking. J Stud Alcohol Drugs 69(5):695–702
Liang JH, Chen F, Krstew E, Cowen MS, Carroll FY, Crawford D et al (2006) The GABA(B) receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats. Neuropharmacology 50(5):632–639. https://doi.org/10.1016/j.neuropharm.2005.11.011
Liang J and Olsen RW (2014) Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors. Acta Pharmacol Sin 35(8):981–93. https://doi.org/10.1038/aps.2014.50
Lieberman DZ, Huang SW (2008) A technological approach to reaching a hidden population of problem drinkers. Psychiatr Serv 59(3):297–303. https://doi.org/10.1176/appi.ps.59.3.2910.1176/ps.2008.59.3.297
Loeber S, Croissant B, Heinz A, Mann K, Flor H (2006) Cue exposure in the treatment of alcohol dependence: effects on drinking outcome, craving and self-efficacy. Br J Clin Psychol 45(Pt 4):515–529. https://doi.org/10.1348/014466505X82586
Long D, Long B, Koyfman A (2017) The emergency medicine management of severe alcohol withdrawal. Am J Emerg Med 35(7):1005–1011. https://doi.org/10.1016/j.ajem.2017.02.002
Lyon J (2017) More treatments on deck for alcohol use disorder. JAMA 317(22):2267–2269. https://doi.org/10.1001/jama.2017.4760
Maccioni P, Zaru A, Loi B, Lobina C, Carai MA, Gessa GL et al (2012) Comparison of the effect of the GABABeta receptor agonist, baclofen, and the positive allosteric modulator of the GABAB receptor, GS39783, on alcohol self-administration in 3 different lines of alcohol-preferring rats. Alcohol Clin Exp Res 36(10):1748–1766. https://doi.org/10.1111/j.1530-0277.2012.01782.x
Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW (2013) Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 108(2):275–293. https://doi.org/10.1111/j.1360-0443.2012.04054.x
Majer JM, Jason LA, Ferrari JR, Miller SA (2011) 12-step involvement among a U.S. national sample of Oxford House residents. J Subst Abus Treat 41(1):37–44. https://doi.org/10.1016/j.jsat.2011.01.010
Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR (2009) Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend 99(1–3):345–349. https://doi.org/10.1016/j.drugalcdep.2008.07.018
Martinotti G, di Nicola M, Frustaci A, Romanelli R, Tedeschi D, Guglielmo R et al (2010) Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction 105(2):288–299. https://doi.org/10.1111/j.1360-0443.2009.02792.x
Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A (2014) Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med 174(1):70–77. https://doi.org/10.1001/jamainternmed.2013.11950
Maurage P, Grynberg D, Noel X, Joassin F, Hanak C, Verbanck P et al (2011) The “reading the mind in the eyes” test as a new way to explore complex emotions decoding in alcohol dependence. Psychiatry Res 190(2–3):375–378. https://doi.org/10.1016/j.psychres.2011.06.015
McCaul ME, Wand GS, Stauffer R, Lee SM, Rohde CA (2001) Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-pituitary-adrenal axis activation. Neuropsychopharmacology 25(4):537–547. https://doi.org/10.1016/S0893-133X(01)00241-X
McDonell MG, Howell DN, McPherson S, Cameron JM, Srebnik D, Roll JM, Ries RK (2012) Voucher-based reinforcement for alcohol abstinence using the ethyl-glucuronide alcohol biomarker. J Appl Behav Anal 45(1):161–165. https://doi.org/10.1901/jaba.2012.45-161
McGovern MP, Carroll KM (2003) Evidence-based practices for substance use disorders. Psychiatr Clin North Am 26(4):991–1010
McQueen J, Howe TE, Allan L, Mains D, Hardy V (2011) Brief interventions for heavy alcohol users admitted to general hospital wards. Cochrane Database Syst Rev 8:CD005191. https://doi.org/10.1002/14651858.CD005191.pub3
Medina KL, McQueeny T, Nagel BJ, Hanson KL, Schweinsburg AD, Tapert SF (2008) Prefrontal cortex volumes in adolescents with alcohol use disorders: unique gender effects. Alcohol Clin Exp Res 32(3):386–394. https://doi.org/10.1111/j.1530-0277.2007.00602.x
Mellentin AI, Skot L, Nielsen B, Schippers GM, Nielsen AS, Stenager E, Juhl C (2017) Cue exposure therapy for the treatment of alcohol use disorders: a meta-analytic review. Clin Psychol Rev 57:195–207. https://doi.org/10.1016/j.cpr.2017.07.006
Miller WR, Rollnick S (2009) Ten things that motivational interviewing is not. Behav Cogn Psychother 37(2):129–140. https://doi.org/10.1017/S1352465809005128
Miller WR, Rollnick S (2014) The effectiveness and ineffectiveness of complex behavioral interventions: impact of treatment fidelity. Contemp Clin Trials 37(2):234–241. https://doi.org/10.1016/j.cct.2014.01.005
Miller WR, Rose GS (2009) Toward a theory of motivational interviewing. Am Psychol 64(6):527–537. https://doi.org/10.1037/a0016830
Minozzi S, Amato L, Vecchi S, Davoli M (2010) Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev 3:CD005064. https://doi.org/10.1002/14651858.CD005064.pub3
Minozzi, S., Saulle, R., & Rösner, S. (2017). Baclofen for alcohol use disorder. 2017(2), 1–15. doi:https://doi.org/10.1002/14651858.CD012557
Mishra BR, Nizamie SH, Das B, Praharaj SK (2010) Efficacy of repetitive transcranial magnetic stimulation in alcohol dependence: a sham-controlled study. Addiction 105(1):49–55. https://doi.org/10.1111/j.1360-0443.2009.02777.x
Mishra BR, Praharaj SK, Katshu MZ, Sarkar S, Nizamie SH (2015) Comparison of anticraving efficacy of right and left repetitive transcranial magnetic stimulation in alcohol dependence: a randomized double-blind study. J Neuropsychiatry Clin Neurosci 27(1):e54–e59. https://doi.org/10.1176/appi.neuropsych.13010013
Muench, F., van Stolk-Cooke, K., Kuerbis, A., Stadler, G., Baumel, A., Shao, S., ... Morgenstern, J. (2017). A randomized controlled pilot trial of different mobile messaging interventions for problem drinking compared to weekly drink tracking. PLoS One, 12(2), e0167900. doi:https://doi.org/10.1371/journal.pone.0167900
Muller UJ, Sturm V, Voges J, Heinze HJ, Galazky I, Buntjen L et al (2016) Nucleus accumbens deep brain stimulation for alcohol addiction—safety and clinical long-term results of a pilot trial. Pharmacopsychiatry 49(4):170–173. https://doi.org/10.1055/s-0042-104507
Nakamura-Palacios, E. M., de Almeida Benevides, M. C., da Penha Zago-Gomes, M., de Oliveira, R. W., de Vasconcellos, V. F., de Castro, L. N., ... Fregni, F. (2012). Auditory event-related potentials (P3) and cognitive changes induced by frontal direct current stimulation in alcoholics according to Lesch alcoholism typology. Int J Neuropsychopharmacol, 15(5), 601–616. doi:https://doi.org/10.1017/S1461145711001040
National Institute for Health and Care Excellence (2011) Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. The British Psychological Society and The Royal College of Psychiatrists, London
NIDA (2012) Principles of drug addiction treatment: a research-based guide (third edition)
Office of the Surgeon General (2016) Reports of the surgeon general. In: Facing addiction in America: the surgeon general’s report on alcohol, drugs, and health (Chapter 4. Early Intervention, treatment and management of substance use disorders). Washington (DC): US Department of Health and Human Services
O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology 160(1):19–29. https://doi.org/10.1007/s002130100919
Ooteman W, Koeter MW, Verheul R, Schippers GM, van den Brink W (2007) The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. Eur Neuropsychopharmacol 17(8):558–566. https://doi.org/10.1016/j.euroneuro.2007.02.012
Pang TY, Hannan AJ, Lawrence AJ (2018) Novel approaches to alcohol rehabilitation: modification of stress-responsive brain regions through environmental enrichment. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2018.02.021
Pani PP, Trogu E, Pacini M, Maremmani I (2014) Anticonvulsants for alcohol dependence. Cochrane Database Syst Rev 2:CD008544. https://doi.org/10.1002/14651858.CD008544.pub2
Pastor A, Jones DM, Currie J (2012) High-dose baclofen for treatment-resistant alcohol dependence. J Clin Psychopharmacol 32(2):266–268. https://doi.org/10.1097/JCP.0b013e31824929b2
Perry CJ (2016) Cognitive decline and recovery in alcohol abuse. J Mol Neurosci 60(3):383–389. https://doi.org/10.1007/s12031-016-0798-4
Perry CJ, Lawrence AJ (2017a) Addiction, cognitive decline and therapy: seeking ways to escape a vicious cycle. Genes Brain Behav 16(1):205–218. https://doi.org/10.1111/gbb.12325
Perry CJ, Lawrence AJ (2017b) Hurdles in basic science translation. Front Pharmacol 8:478. https://doi.org/10.3389/fphar.2017.00478
Pignon B, Labreuche J, Auffret M, Gautier S, Deheul S, Simioni N, Cottencin O, Bordet R, Duhamel A Rolland B (2017) The dose-effect relationship of baclofen in alcohol dependence: a 1-year cohort study. Hum Psychopharmacol, 32(4). doi:https://doi.org/10.1002/hup.2593
Project Match Research Group (1998) Matching alcoholism treatments to client heterogeneity: project MATCH three-year drinking outcomes. Alcohol Clin Exp Res 22(6):1300–1311
Randall PA, Jaramillo AA, Frisbee S, Besheer J (2015) The role of varenicline on alcohol-primed self-administration and seeking behavior in rats. Psychopharmacology 232(14):2443–2454. https://doi.org/10.1007/s00213-015-3878-1
Ray LA, Hutchison KE (2004) A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 28(12):1789–1795
Ray LA, Hutchison KE (2007) Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 64(9):1069–1077. https://doi.org/10.1001/archpsyc.64.9.1069
Ray, L. A., Miranda, R. Jr., Mac Killop, J., McGeary, J., Tidey, J. W., Rohsenow, D. J., … Monti, P. M. (2009). A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol, 17(2), 122–129. doi:https://doi.org/10.1037/a0015700
Reynaud M, Aubin HJ, Trinquet F, Zakine B, Dano C, Dematteis M, Trojak B, Paille F, Detilleux M (2017) A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients-the ALPADIR study. Alcohol Alcohol 52(4):439–446. https://doi.org/10.1093/alcalc/agx030
Rice SL, Hagler KJ, Tonigan JS (2014) Longitudinal trajectories of readiness to change: alcohol use and help-seeking behavior. J Stud Alcohol Drugs 75(3):486–495
Riper H, Andersson G, Hunter SB, de Wit J, Berking M, Cuijpers P (2014) Treatment of comorbid alcohol use disorders and depression with cognitive-behavioural therapy and motivational interviewing: a meta-analysis. Addiction 109(3):394–406. https://doi.org/10.1111/add.12441
Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M (2010a) Acamprosate for alcohol dependence. Cochrane Database Syst Rev 9:CD004332. https://doi.org/10.1002/14651858.CD004332.pub2
Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M (2010b) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 12:CD001867. https://doi.org/10.1002/14651858.CD001867.pub2
Rossi S, Hallett M, Rossini PM, Pascual-Leone A, Safety of T. M. S. Consensus Group (2009) Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 120(12):2008–2039. https://doi.org/10.1016/j.clinph.2009.08.016
Rubio G, Lopez-Munoz F, Ferre F, Martinez-Gras I, Ponce G, Pascual JM et al (2010) Effects of zonisamide in the treatment of alcohol dependence. Clin Neuropharmacol 33(5):250–253. https://doi.org/10.1097/WNF.0b013e3181f0ed9a
Rupp CI, Kemmler G, Kurz M, Hinterhuber H, Fleischhacker WW (2012) Cognitive remediation therapy during treatment for alcohol dependence. J Stud Alcohol Drugs 73(4):625–634
Rupp CI, Derntl B, Osthaus F, Kemmler G, Fleischhacker WW (2017) Impact of social cognition on alcohol dependence treatment outcome: poorer facial emotion recognition predicts relapse/dropout. Alcohol Clin Exp Res 41(12):2197–2206. https://doi.org/10.1111/acer.13522
Sayegh CS, Huey SJ, Zara EJ, Jhaveri K (2017) Follow-up treatment effects of contingency management and motivational interviewing on substance use: a meta-analysis. Psychol Addict Behav 31(4):403–414. https://doi.org/10.1037/adb0000277
Schomerus G, Lucht M, Holzinger A, Matschinger H, Carta MG, Angermeyer MC (2011) The stigma of alcohol dependence compared with other mental disorders: a review of population studies. Alcohol Alcohol 46(2):105–112. https://doi.org/10.1093/alcalc/agq089
Skinner MD, Lahmek P, Pham H, Aubin HJ (2014) Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One 9(2):e87366. https://doi.org/10.1371/journal.pone.0087366
Soyka M (2014) Nalmefene for the treatment of alcohol dependence: a current update. Int J Neuropsychopharmacol 17(4):675–684. https://doi.org/10.1017/S1461145713001284
Soyka M (2016) Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmacother 17(4):619–626. https://doi.org/10.1517/14656566.2016.1146689
Soyka M, Muller CA (2017) Pharmacotherapy of alcoholism—an update on approved and off-label medications. Expert Opin Pharmacother 18(12):1187–1199. https://doi.org/10.1080/14656566.2017.1349098
Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE (2007) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A 104(30):12518–12523. https://doi.org/10.1073/pnas.0705368104
Stoner SA, Arenella PB, Hendershot CS (2015) Randomized controlled trial of a mobile phone intervention for improving adherence to naltrexone for alcohol use disorders. PLoS One 10(4):e0124613. https://doi.org/10.1371/journal.pone.0124613
Stormark KM, Laberg JC, Nordby H, Hugdahl K (1998) Heart rate responses indicate locked-in attention in alcoholics immediately prior to drinking. Addict Behav 23(2):251–255
Suchankova P, Yan J, Schwandt ML, Stangl BL, Jerlhag E, Engel JA, Hodgkinson CA, Ramchandani VA, Leggio L (2017) The Leu72Met polymorphism of the prepro-ghrelin gene is associated with alcohol consumption and subjective responses to alcohol: preliminary findings. Alcohol Alcohol 52(4):425–430. https://doi.org/10.1093/alcalc/agx021
Suffoletto B, Kristan J, Callaway C, Kim KH, Chung T, Monti PM, Clark DB (2014) A text message alcohol intervention for young adult emergency department patients: a randomized clinical trial. Ann Emerg Med 64(6):664–672 e664. https://doi.org/10.1016/j.annemergmed.2014.06.010
Suffoletto B, Kristan J, Chung T, Jeong K, Fabio A, Monti P, Clark DB (2015) An interactive text message intervention to reduce binge drinking in young adults: a randomized controlled trial with 9-month outcomes. PLoS One 10(11):e0142877. https://doi.org/10.1371/journal.pone.0142877
Sundstrom C, Gajecki M, Johansson M, Blankers M, Sinadinovic K, Stenlund-Gens E, Berman AH (2016) Guided and unguided internet-based treatment for problematic alcohol use—a randomized controlled pilot trial. PLoS One 11(7):e0157817. https://doi.org/10.1371/journal.pone.0157817
Tait RJ, Christensen H (2010) Internet-based interventions for young people with problematic substance use: a systematic review. Med J Aust 192(11 Suppl):S15–S21
Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R Jr, McGeary JE et al (2008) Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 32(1):58–66. https://doi.org/10.1111/j.1530-0277.2007.00545.x
Torrens M, Fonseca F, Mateu G, Farre M (2005) Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend 78(1):1–22. https://doi.org/10.1016/j.drugalcdep.2004.09.004
Trim RS, Schuckit MA, Smith TL (2013) Predictors of initial and sustained remission from alcohol use disorders: findings from the 30-year follow-up of the San Diego Prospective Study. Alcohol Clin Exp Res 37(8):1424–1431. https://doi.org/10.1111/acer.12107
Voges J, Muller U, Bogerts B, Munte T, Heinze HJ (2013) Deep brain stimulation surgery for alcohol addiction. World Neurosurg 80(3–4):S28 e21–31. https://doi.org/10.1016/j.wneu.2012.07.011
Walker DD, Roffman RA, Picciano JF, Stephens RS (2007) The check-up: in-person, computerized, and telephone adaptations of motivational enhancement treatment to elicit voluntary participation by the contemplator. Subst Abuse Treat Prev Policy 2:2. https://doi.org/10.1186/1747-597X-2-2
Walter M, Gerhard U, Gerlach M, Weijers HG, Boening J, Wiesbeck GA (2006) Cortisol concentrations, stress-coping styles after withdrawal and long-term abstinence in alcohol dependence. Addict Biol 11(2):157–162. https://doi.org/10.1111/j.1369-1600.2006.00018.x
Warden A, Erickson E, Robinson G, Harris RA, Mayfield RD (2016) The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies. Pharmacogenomics 17(18):2081–2096. https://doi.org/10.2217/pgs-2016-0062
White A, Kavanagh D, Stallman H, Klein B, Kay-Lambkin F, Proudfoot J et al (2010) Online alcohol interventions: a systematic review. J Med Internet Res 12(5):e62. https://doi.org/10.2196/jmir.1479
WHO (2014). Global status report on alcohol and health
Wright J (1978) Endocrine effects of alcohol. Clin Endocrinol Metab 7(2):351–367
You CW, Chen YC, Chen CH, Lee CH, Kuo PH, Huang MC, Chu HH (2017) Smartphone-based support system (SoberDiary) coupled with a Bluetooth breathalyser for treatment-seeking alcohol-dependent patients. Addict Behav 65:174–178. https://doi.org/10.1016/j.addbeh.2016.10.017
Zilverstand A, Parvaz MA, Moeller SJ, Goldstein RZ (2016) Cognitive interventions for addiction medicine: understanding the underlying neurobiological mechanisms. Prog Brain Res 224:285–304. https://doi.org/10.1016/bs.pbr.2015.07.019
Funding
This work was supported by a National Health and Medical Research Council Project Grant (AJL, 1105741), a National Health and Medical Research Council Principal Research Fellowship (AJL, 1116930), a National Health and Medical Research Council/Australian Research Council Fellowship (CJP, 1107144), and the Victorian State Government Operational Infrastructure Scheme.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Rights and permissions
About this article
Cite this article
Campbell, E.J., Lawrence, A.J. & Perry, C.J. New steps for treating alcohol use disorder. Psychopharmacology 235, 1759–1773 (2018). https://doi.org/10.1007/s00213-018-4887-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-018-4887-7